ALX Oncology Holdings Balance Sheet Health
Financial Health criteria checks 5/6
ALX Oncology Holdings has a total shareholder equity of $159.3M and total debt of $9.8M, which brings its debt-to-equity ratio to 6.1%. Its total assets and total liabilities are $214.6M and $55.3M respectively.
Key information
6.1%
Debt to equity ratio
US$9.77m
Debt
| Interest coverage ratio | n/a |
| Cash | US$156.72m |
| Equity | US$159.32m |
| Total liabilities | US$55.30m |
| Total assets | US$214.62m |
Recent financial health updates
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Recent updates
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Sep 12ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Jun 27ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 11ALX Oncology prices upsized stock offering at $76
Dec 10Financial Position Analysis
Short Term Liabilities: ALXO's short term assets ($168.7M) exceed its short term liabilities ($38.4M).
Long Term Liabilities: ALXO's short term assets ($168.7M) exceed its long term liabilities ($16.9M).
Debt to Equity History and Analysis
Debt Level: ALXO has more cash than its total debt.
Reducing Debt: ALXO's debt to equity ratio has reduced from 60% to 6.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALXO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALXO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.